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Abstract
Introduction: The mechanism by which intra-articular injection of hyaluronan (HA) ameliorates joint pathology is
unknown. Animal studies have shown that HA can reduce synovial activation, periarticular fibrosis and cartilage
erosion; however, its specific effects on the different cell types involved remain unclear. We have used the TTR
(TGFbeta1 injection and Treadmill Running) model of murine osteoarthritis (OA), which exhibits many OA-like
changes, including synovial activation, to examine in vivo tissue-specific effects of intra-articular HA.
Methods: The kinetics of clearance of fluorotagged HA from joints was examined with whole-body imaging. Naïve
and treated knee joints were examined macroscopically for cartilage erosion, meniscal damage and fibrosis.
Quantitative histopathology was done with Safranin O for cartilage and with Hematoxylin & Eosin for synovium.
Gene expression in joint tissues for Acan, Col1a1, Col2a1, Col3a1, Col5a1, Col10a1, Adamts5 and Mmp13 was done
by quantitative PCR. The abundance and distribution of aggrecan, collagen types I, II, III, V and X, ADAMTS5 and
MMP13 were examined by immunohistochemistry.
Results: Injected HA showed a half-life of less than 2 h in the murine knee joint. At the tissue level, HA protected
against neovascularization and fibrosis of the meniscus/synovium and maintained articular cartilage integrity in
wild-type but not in Cd44 knockout mice. HA injection enhanced the expression of chondrogenic genes and
proteins and blocked that of fibrogenic/degradative genes and proteins in cartilage/subchondral bone, whereas it
blocked activation of both groups in meniscus/synovium. In all locations it reduced the expression/protein for
Mmp13 and blocked Adamts5 expression but not its protein abundance in the synovial lining.
Conclusions: The injection of HA, 24 h after TGFbeta1 injection, inhibited the cascade of OA-like joint changes
seen after treadmill use in the TTR model of OA. In terms of mechanism, tissue protection by HA injection was
abrogated by Cd44 ablation, suggesting that interaction of the injected HA with CD44 is central to its protective
effects on joint tissue remodeling and degeneration in OA progression.
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Introduction
The generally accepted, albeit limited, benefit of hyaluro-
nan (HA) injection for patients with osteoarthritis (OA)
[1] has been accompanied by basic research, initiated in
about 1996 [2], to unravel the mechanism(s) of this effect.
Studies in OA models in rats, rabbits, dogs and sheep have
indicated that HA has pleitrophic effects, such as anti-
apoptotic, anti-inflammatory, anti-angiogenic and anti-
fibrotic. For example, HA treatment of rats after joint
immobilization [3] or intra-articular IL-1 injection [4] pro-
tects against cartilage degeneration, apparently due to
both anti-apoptotic and anti-inflammatory effects. More-
over, OA-like changes after ovine anterior cruciate liga-
ment transection (ACLT) or meniscectomy include
fibrosis and neovascularization of the synovium, and this
pathology is also ameliorated by HA injections [5,6]. In
the same context, extended strenuous uphill running of
rats [7] results in a fibrous deposition in the infrapatellar
fat pad and this is prevented by HA injection during the
exercise period. These inhibitory effects of HA on fibropla-
sia in animal joint tissues appear to be very relevant to
human treatments since human OA has been associated
with activation of pro-fibrogenic genes in cartilage [8,9]
and overt fibrosis of the synovium [10-12], subchondral
bone [13,14] and vastus medialis muscle [15].
We have reported that for mice, intra-articular injections
of TGFbeta1 prior to treadmill running (TTR model)
results in mechanically-induced fibrotic remodeling and
erosion of the articular cartilage as well as synovial hyper-
plasia and fibrosis [16]. Notably, these pathologies did not
develop in ADAMTS5-deficient mice, apparently because
the absence of ADAMTS5 can prevent TGFbeta1-induced
fibrogenesis (via Smad2/3), and promote TGFbeta1/BMP-
induced chondrogenesis (via Smad1/5/8), a switch which
has been demonstrated in newborn fibroblasts [17] and
bone marrow derived mesenchymal stem cells (MSCs)
(Gorski D and Plaas A, unpublished). Further, the chon-
drogenic effect of Adamts5 ablation in dermal fibroblasts
in vivo was shown to be eliminated, and fibrogenic path-
ways activated by concomitant ablation of Cd44 [17].
Our primary goal in the current work was to use this
murine model of OA to determine whether HA injection
abrogates the fibrogenic cell and tissue changes which
occur in the synovium/meniscus and cartilage/subchon-
dral bone compartments in this model. As part of this
objective we also studied the effect of HA injection on the
expression and abundance of the two metalloproteases,
ADAMTS5 and MMP13, which are now primarily
invoked to explain tissue degeneration in murine and
human OA [18]. In addition, studies in isolated chondro-
cytes and synoviocytes [19-22] have suggested a role for
CD44 in HA-mediated inhibition of expression of MMP1/
13 and ADAMTS4/5 by these cell types. To determine
whether CD44 might also be required for the effects of
HA in vivo, we have used Cd44-/- mice in the TTR model
of OA.
Materials and methods
Osteoarthritis model and experimental groups
The murine TTR (TGFbeta1 injection plus Treadmill
Running) model is described in detail elsewhere [16] and
also summarized in Figure 1A. Male mice (wild type and
Cd44-/- strains [17] in the C57BL/6 background, age
12 weeks) were bred in-house, and all animal protocols
were approved by the Rush University Medical Center
Animal Care and Use Committee. HA or saline injections
were given one day after the second TGFbeta1 injection,
and the effect was studied for acute changes and longer
term changes (see Figure 1A for group names). For the
acute study, the groups included: a) untreated mice
(Naïve), b) mice sacrificed two days after the second
TGFbeta1 injection without further treatment (Acute),
and c) mice sacrificed one day after HA injection (Acute
+HA). For the longer-term study, the three groups were:
a) mice sacrificed on Day 19 after the two TGFbeta1 injec-
tions and 14 days treadmill running (TTR), b) mice sacri-
ficed on Day 19 after TGFbeta1 treatment, HA injection
and 14 days of treadmill running (TTR+HA) and mice
sacrificed on Day 19 after TGFbeta1 treatment, saline
injection and 14 days of treadmill running (TTR+SA). For
the study with Cd44-/- mice, the groups analyzed were
Naive, TTR and TTR+HA.
Hyaluronan preparations, intra-articular delivery and
dwell time
HA (Supartz, Seikagaku Co., Tokyo, Japan 620-1170 kDa,
average 900 kDa) was diluted with sterile saline and 7.5 ug
in 10 ul was injected through the patellar ligament into
the joint space of the right knee with a 30-gauge needle on
an insulin syringe. Fluorescein isothiocyanate (FITC)-
labeled HA [23] was chromatographed on Sephacryl
S-1000 (GE Healthcare Biosciences, Piscataway, NJ, USA)
in 0.1 M sodium acetate, pH 7.0 [24] and the eluant moni-
tored for fluorescence. Essentially all of the fluorescence
was in high molecular weight HA (absorbance at 214 nm,
A214) as shown by exclusion from the gel (Figure 1A). To
check the accuracy of injection and the dwell time of HA
in the joint, the FITC-labeled HA was injected into the
knee of naïve mice (n = 4) and also mice which had been
injected into the knee 24 h earlier with 200 ng active
TGFbeta1 (n = 4). At 0, 2, 5 and 18 h, mice were placed in
a Kodak FX System (Carestream Health Inc., Rochester,
NY, USA) for X-ray and fluorescence analysis. Accuracy of
injection was confirmed (Figure 1C) and the bulk of the
injected HA were eliminated (from both naïve and
TGFbeta1 injected joints) in the first 2 h, although traces
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could be detected at 18 h (Figure 1D). High fluorescence
was also seen in the urethra at 5 h (Figure 1D), probably
derived from the short-lived HA pool released from the
joint in the first 2 h.
Macroscopic imaging and histopathology
Global joint pathology [25] was evaluated by India Ink
application followed by surface photography under a
Nikon dissecting microscope (SMZ1000, X6) (Nikon
Instruments Inc., Melville, NY, USA). Abnormalities were
evaluated blindly, paying particular attention to the
deposition of fibrotic tissue around the menisci and along
the medial and lateral aspects of the tibial plateau, femoral
condyles and patella groove margins, and any evidence of
an associated cartilage surface roughening or erosion (see
Figure 2). The reproducibility and discriminatory power of
macroscopic evaluation was established earlier [25,26];
however, scoring was not used here because of the obvious
and marked effects of HA on global pathology, histo-
pathology and immunohistochemistry.
For histology, intact mouse knees were dissected away
from the skin, fixed with 10% neutral buffered formalin
for a minimum of three days, and decalcified in 5%
ethylenediaminetetraacetic acid (EDTA)/phosphate-buf-
fered saline (PBS) for three weeks. Specimens were par-
affin embedded and about 180 thin sections (6 um)
were taken across the entire joint from medial to lateral
in the sagittal plane. Slides 1 to 30, 31 to 60 and 61 to
90 (two adjacent sections per slide) spanned the medial,
central groove and lateral compartments, respectively.
For histopathological assays, deparaffinized slides 1, 11,
21, 31, 41, 51, 61, 71 and 81 were stained with Safranin
O and slides 2, 12, 22, 32, 42, 52, 62, 72, and 82 were
stained with hematoxylin/eosin.
The mean stainable cartilage in joints from each
experimental group was determined as follows: the area
(tibia plus femur) of Safranin O positive tissue was
obtained by visual tracing (see Figure 3A), coupled to the
area function of the NIH image analysis software Image J
(Bethesda, MD, USA). Areas were determined on each of
32 equally spaced sagittal sections taken across the lateral
compartment of the right joint of each mouse. The total
area for each mouse was the summed area values of the
32 sections. The mean total area (+/-SD) (cartilage
Figure 1 Experimental protocols and elimination of HA from the murine knee joint. (A) The schematic shows details of the time line for
intraarticular injections, treadmill running and time points for tissue collection. (B) Characterization of FITC-labeled HA preparation (620 to 1,170
kDa) by Sephacryl S-1000 chromatography. (C) Fluorescence imaging and x-ray analyses of joints shows accuracy of delivery of FITC-labeled HA
into the joint space. (F, Femur) (D) Whole body fluorescent imaging was used to determine the time course of disappearance from the joint of
FITC-labeled HA (FITC labeled excretory products at 5 h after injection are indicated by **). Procedures are described in detail in the Methods
section.
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volume (arbitrary units) on Figure 3B) was calculated
from the total area for each mouse (N = 6) in each group.
Synovial histopathology was scored essentially as
described [5] on a scale of 0 to 5 for sub intimal fibrosis
and for vascularity. The analysis was done on 16 equally
spaced sagittal sections from the lateral compartment of
each joint stained with hematoxylin/eosin, and only
matching regions of the proximal and distal perimenis-
cal synovium were scored. The mean score for fibrosis
or vascularity for each mouse was the sum of the scores
from the 16 sections divided by 16. The mean scores
(+/-SD) for fibrosis or vascularity in each group (N = 4)
were calculated from the mean score from each mouse
in the group.
Figure 2 Effect of HA injection on macroscopic pathology in the TTR model. Knee joints were carefully opened, and after rinsing with PBS,
India ink was applied to all surfaces with a paint brush and rinsed again. Menisci and articular surfaces were photographed under a Nikon
dissecting microscope (SMZ1000, X6) and images processed with Spot Basic, Diagnostic Instruments, Inc (Sterling Heights, MI, USA). Typical
images of meniscus and cartilage surfaces from naïve joints and joints from each of the three experimental groups at Day 19 (TTR, TTR+HA and
TTR+SA) are shown. Black arrow heads indicate cartilage erosion and black stars indicate fibrotic overgrowth.
Figure 3 Effect of HA injection on cartilage histopathology in the TTR model. (A) Typical Safranin O histology of femoral and tibial
epiphyses from naïve joints and joints of TTR and TTR+HA groups (B). For each of the experimental groups, the mean (+/SD) cartilage volume
was calculated from the area stained with Safranin O as described in the Methods. The dotted lines show typical selections of areas used for
cartilage quantitation.
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Quantitative PCR
A total of 16 naïve mice and 24 experimental mice for
each treatment group (TTR, TTR+HA and TTR+SA)
were analyzed as follows: articular surfaces from two mice
were combined for each assay and these pools (n = 8 to
12) were analyzed separately. Cartilage-rich tissue was
pooled from tibial and femoral surfaces by a fine scalpel
cut across the surfaces. Histological inspection showed
that all cartilage samples contained subchondral bone, but
no growth plate cartilage, so that these samples are
described as cartilage/subchondral bone throughout. The
menisci and synovial tissue were harvested. This was done
by making a circular incision along the synovium/periarti-
cular attachments on the medial and lateral tibial plateaus,
followed by cutting the anterior and posterior attachments
of both menisci. For menisci/synovial tissue analysis, two
tissue pools from each experimental group were prepared,
with each derived from 8 to 12 mice. This was necessitated
by the relatively low content/yield of mRNA from menis-
cus/synovium relative to cartilage/subchondral bone
samples.
All specimens were harvested into RNALater and stored
at -20C before analyses. RNA was prepared by thawing
tissues on ice, rinsing with fresh RNALater (Qiagen,
Valencia, CA, USA), snap-freezing in liquid nitrogen and
pulverizing, prior to application of the PerfectPure RNA
Kit for Fibrous Tissue (5 PRIME). Taqman-based QPCR
(Life Technologies, Carlsbad, CA, USA) was done with
inventoried primers for mouse Acan, Col3a1 and Adamts5
as described [17]. Primers for Col1a1, Col5a1, Col10a1,
and Mmp13 were Mm00801666_g1, Mm00489342_m1,
Mm004 87041_m1 and Mm00439491_m1, respectively.
QPCR values of meniscus/synovium used for comparisons
between experimental groups were the average of the data
from the two pools, with the difference between the results
being < 20% of the average pool value.
Immunohistochemistry
Anti-collagen type I (ab34710), anti-collagen type II
(ab34712), anti-collagen type III (ab7778), anti-collagen
type V (ab7046), anti-collagen type × (ab58632) and anti-
MMP13 (ab75606) were purchased from Abcam UK
(Cambridge, MA, USA). Aggrecan and ADAMTS5 were
detected as described [27] using anti-DLS and anti-KNG
respectively. For each joint, the two sections on slides 3 to
10, 13 to 20, 23 to 30, 63 to 70, 73 to 80 and 83 to 90 were
taken for immunohistochemistry. Briefly, deparaffinized
sections were incubated in primary antibodies or non-
immune IgG (both 10 ug/ml) overnight at 4°C. Sections to
be stained with anti-MMP13, anti-ADAMTS5, anti-
collagen type X and anti-collagen type II were digested
with proteinase K to obtain optimal antigen exposure.
Sections were next incubated with biotinylated goat anti-
rabbit IgG, HRP-labeled avidin-biotin complex and 3, 3’-
diaminobenzidine substrate. Nuclei and cartilage matrix
were counter-stained with methyl green as described by
Vector Labs, Burlingame, CA, USA. It should be noted
that this IHC staining procedure predominantly stained
antigens in the pericellular/cell-associated space and that
antigen retrieval procedures, such as proteinase K, chon-
droitinase or hyaluronidase pretreatment, but did not sig-
nificantly enhance general matrix staining. Further, all
antibodies were shown to exhibit high specificity as deter-
mined with controls employing only the secondary anti-
body. Since the differences in signal intensity and
distribution (with multiple antibodies on multiple sec-
tions) between treatment groups were highly reproducible
and clearly biologically relevant, no scoring system or
statistical evaluation was developed for this analysis.
Statistical analysis
For those experiments where data were obtained sepa-
rately from six or more individual mice (N > 5), two-way
ANOVA for independent samples was used as an initial
analysis, followed by Students t-test for comparisons
between the most relevant pairs of groups. For menisci/
synovial tissue no statistical analysis was applied.
Results
Effect of HA injection on macroscopic pathology and
cartilage loss in the TTR Model
A schematic describing the time line of the model, treat-
ment for each experimental group and tissue harvest
points is shown in Figure 1A. The macroscopic pathology
seen on the surfaces of menisci, tibia, femur and the
patellar groove in the TTR model (Figure 2, Row 2), rela-
tive to the appearance of naive joints (Figure 2, Row 1), is
shown. As described previously [16,25] in this model,
there is a deposition of fibrotic tissue around the menisci
and along the medial and lateral aspects of the tibial pla-
teau, femoral condyles and patella groove margins, which
is most likely derived from activation of synovium and
periosteum by TGFbeta1 injection. Furthermore, this
remodeling is commonly associated with cartilage surface
roughening or erosion.
The effects of HA injection (TTR+HA) relative to sal-
ine injection (TTR+SA) is illustrated in the two bottom
rows. When HA was injected on Day 4 after the
TGFbeta1 but before treadmill running (Figure 2, TTR
+HA group), a marked protection against the develop-
ment of these overgrowths and cartilage erosion at all
sites was observed. However, when saline was injected
instead of HA (Figure 2, TTR+SA) there was no protec-
tive effect on macroscopic pathology.
To further evaluate cartilage protective effects of intra-
articular HA injection in the TTR model, Safranin O-
stained histological sections were prepared from the knees
of six mice from each of the naive, TTR and TTR+HA
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groups. Typical images of the femoral and tibial surfaces
are provided in Figure 3A. The TTR group generally
showed thinner and less intensely stained cartilage than
the naïve and TTR+HA groups, consistent with the
macroscopic findings. When the mean volume of cartilage
in the knee joints of mice from the four different groups
(Naïve, TTR, TTR+HA and TTR+SA) was estimated by
SafraninO staining (see Methods), the TTR model resulted
in an approximately 70% loss of cartilage compared to
naïve mice (P = 0.002) and injection of HA (TTR+HA) lar-
gely prevented this loss, whereas with injection of saline
(TTR+SA) the loss remained (P = 0.001) (Figure 3B).
Effect of HA injection on acute and long-term
histopathological changes in perimeniscal synovium
The effect of HA on the response of synovial tissue to
TGFbeta1 (Acute) and TTR was also studied, with four
mice in each treatment group, and typical H/E-stained
sections from both sets are shown in Figure 4A. A cellular
hyperplastic response (H) of both lining and stromal cells
was induced by TGFbeta1 injection alone (Acute) and HA
injection (Acute +HA) had little or no effect on this early
process. After treadmill running, the synovium exhibited
extensive fibrotic deposits (F) and these were also fre-
quently populated by multiple blood vessels (V). HA injec-
tion (TTR+HA) essentially prevented the fibrotic response
in the stromal region and the lining, blocked the vascular
response and restored the adipocyte-rich naive appearance
of the stroma. When naive mice were run on the treadmill
for two weeks there was no sign of changes in the perime-
niscal synovium (not shown). To provide quantitative data
on these effects between the different treatment groups,
we applied a multi-parameter scoring system (see Meth-
ods) to each section and the mean +/-SD data (N = 4) are
provided on Figure 4B. This showed clearly that injection
of HA on Day 4 essentially prevented the appearance of
fibrotic remodeling and vascular changes by Day 19,
whereas saline injection was ineffective in this regard.
Effect of HA injection on expression of chondrogenic and
fibrogenic genes in cartilage/subchondral bone
Our previous studies of this model showed that alterations
in macroscopic, chondrogenic and fibrotic tissue responses
most readily explained the effects of Adamts5 ablation [16]
and HA injection [25]; however, we did not assess specific
cellular responses in those studies. Here we have deter-
mined expression levels of the chondrogenic genes Acan,
Col2a1 and Col10a1 and the fibrogenic genes Col1a1,
Col3a1 and Col5a1 in all experimental groups (Naive,
Acute, TTR, TTR+HA and TTR+SA) with the tissues
separated into cartilage/subchondral bone and meniscus/
synovium. This showed that TGFbeta1 injection alone
Figure 4 Effect of injection of HA on synovial histology at Day 4 and Day 19 of model. (A) Typical images of proximal (Prox) and distal
(Dist) regions of the perimeniscal synovium from Hematoxylin&Eosin stained sections are shown for five experimental groups (Naïve, Acute,
Acute+ HA, TTR and TTR+HA). Histological changes were identified as: hyperplasia (H), fibrosis (F) and neovascularization (V). (B) Mean pathology
scores for fibrosis (F) and vascularization (V) were obtained from 16 stained sections per mouse (n = 4 mice for each of the four experimental
groups Naïve, TTR, TTR+HA, TTR+SA) and statistical analysis performed as described in the Methods section.
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increased the cartilage/subchondral bone expression of
Acan (2.39-fold) and Col2a1 (5.77-fold), whereas Col10a1
was essentially unaffected (Table 1). The increased expres-
sion of Acan and Col2a1 was normalized somewhat after
the complete TTR, but it was activated, beyond the levels
seen with TGFbeta1 alone, in the TTR+HA group.
TGFbeta1 injection alone also increased the expression of
Col1a1, Col3a1 and Col5a1 by 36.5-fold, 2.97-fold and
2.80-fold, respectively (Table 2 Acute). With TGFbeta1
injection and treadmill running (TTR) the high level of
Col1a1 expression at Day 5 (Acute group) was maintained,
and Col3a1 and Col5a1 expression was further stimulated
to 13.2-fold and 17.9-fold relative to naive levels. Injection
of HA (TTR+HA) returned Col1a1, Col3a1 and Col5a1
expression to near naive levels, whereas injection of saline
(TTR+SA) did not markedly affect the enhancement of
fibrogenic gene expression seen in TTR. Taken together,
the data in Tables 1 and 2 show that a single injection of
HA on Day 4 of the TTR model (see Figure 1A) maintains
chondrogenic gene expression to Day 19, and also mark-
edly reduces the high level of fibrogenic gene expression
seen at this time without HA injection.
Effect of HA injection on chondrogenic and fibrogenic
proteins in cartilage/subchondral bone
To confirm translation into protein of the chondrogenic
genes (Acan, Col2a1, and Col10a1) and fibrogenic genes
(Col1a1, Col3a1, Col5a), immunohistochemistry was per-
formed on 12 sections from different sagittal planes of
the right lateral tibial compartment of each mouse and
typical results are shown in Figure 5. In general agree-
ment with the gene expression data, TGFbeta1 injection
alone (Figure 5A, Acute) did not markedly alter the num-
ber or location of chondrocytes which were stained for
aggrecan, collagen type II and collagen type X. For the
TTR group, the degenerated cartilage (note roughened
surface) contained cells which were not stained, and also
those which were intensely stained in the pericellular/
cell-associated space, for aggrecan, collagen type II and
collagen type × [28]. Notably, cells staining for these
chondrogenic proteins were also frequently seen in the
calcified cartilage and subchondral bone regions in all
experimental groups that had received TGFbeta1 injec-
tions. In the TTR+HA group, the cartilage surfaces
remained largely intact and appeared similar to naïve car-
tilage. However, the underlying chondrocytes showed
greatly enhanced pericellular/cell-associated staining for
aggrecan when compared to naïve cartilage, a result
which is in keeping with the 3.27-fold increase in Acan
gene expression in cartilage/subchondral bone samples
from HA treated joints (Table 1).
As suggested by the gene expression data, TGFbeta1
injection alone also increased the proportion of chondro-
cytes with pericellular/cell-associated staining for collagen
types I, III and V, most of them localized in groups in the
mid zone of the articular cartilage (Figure 5B, Acute).
Consistent with high gene expression levels for the TTR
group, strong staining for collagen types I and III (and to
some extent collagen type V) was almost exclusively loca-
lized to cells at the surface of the lesions and in the sur-
rounding matrix, whereas chondrocytes in the deeper
layers and the calcified cartilage showed only minimal
staining for the fibrogenic collagens. Notably, and consis-
tent with the gene expression data, HA injection (Figure
5B, TTR+HA) was accompanied by cell groups which
stained for collagen types I, III and V in the protected
articular cartilages. Their presence in the mid zone sug-
gests that they represent those cells which were activated
by TGFbeta1 in the acute phase.
Effect of HA injection on expression of chondrogenic and
fibrogenic genes in meniscus/synovium
Injection of TGFbeta1 alone resulted in a robust activa-
tion (up to 40-fold) of all three chondrogenic genes in
the meniscus/synovium (Table 3 Acute), which is in
marked contrast to the minimal effect of TGFbeta1 on
chondrogenic genes in cartilage/subchondral bone
(Table 1 Acute). This difference may be explained by
proliferation of stromal cells in the synovial lining (see
Figure 4) together with their TGFbeta1-induced differ-
entiation towards a chondrogenic phenotype [29]. For
the TTR group, (Table 3 TTR), expression of the three
Table 1 QPCR of chondrogenic gene expression in cartilage/subchondral bone
acan P Fold4 col2a P Fold4 col102a P Fold4
ΔCT1 ΔCT1 ΔCT1
Naive 3.84 (0.30) 1.00 4.29 (0.25) 1.00 6.33 (0.08) 1.00
Acute 2.58 (0.04) .00012 2.39 1.76 (0.38) .00012 5.77 6.74 (0.39) NS2 0.75
TTR 3.59 (0.34) NS2 1.90 2.82 (0.60) .00142 2.77 6.59 (0.42) NS2 0.83
TTR+HA 2.13 (0.24) .00013 3.27 0.86 (0.19) .00033 10.7 4.82 (0.30) .00013 2.85
TTR+SA 3.36 (0.03) NS3 1.40 2.32 (0. 4) NS3 3.92 6.16 (0.43) NS3 1.12
1relative to GAPDH, mean (SD) ΔCT of 8 pools with 2 mice per pool for Naïve and 12 pools with 2 mice per pool for all 4 treatment groups.
P-values: 2Acute or TTR vs Naive; 3TTR+HA or TTR+SA vs TTR;
4Fold Changes are relative to Naive
NS, not significant
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chondrogenic genes remained elevated in the meniscus/
synovium pool whereas in the TTR+HA group (Table 3),
chondrogenic gene expression was much lower and only
minimally above that seen in the naïve joints. Saline
injection (Table 3 TTR+SA) did not, however, reduce
chondrogenic gene expression in this tissue pool to naïve
levels. TGFbeta1 treatment alone (Table 3 Acute) acti-
vated Col1a1 and Col5a1 expression (102-fold and 4.08-
fold respectively), but there was no effect on Col3a1
expression. For the TTR group, the expression of all
three fibrogenic collagen genes was markedly enhanced
(15- to 30-fold), much as observed for these genes in car-
tilage/subchondral bone from the same group. HA, but
not saline injection, decreased expression of all fibrogenic
genes in the meniscus/synovium tissue pool to essentially
naïve levels (Table 3 TTR+HA).
Effect of HA injection on the abundance of chondrogenic
and fibrogenic proteins in the perimeniscal synovium
In naïve joints, the synovial lining and stromal cells
showed staining for aggrecan and collagen types I, II and
III but not collagen type V (Figure 6). Consistent with
the activation of gene expression (Table 3), the
TGFbeta1-induced hyperplastic lining (L) showed a
strong staining for aggrecan and collagen type II (Figure
6A, Acute). The hyperplastic stromal cell population and
its associated matrix also stained for collagen type II, but
only weakly for aggrecan. The fibrotic tissues in the syno-
vium that developed in the TTR group were also positive
for aggrecan and collagen type II (Figure 6A, black arrow
heads), with the latter being particularly strong in the
extracellular matrix at the synovial/meniscal interface. In
the HA injected joints (TTR+HA) both, cells and matrix
in the synovial lining stained strongly for both collagen
type II and aggrecan, but in keeping with reduced gene
expression (Table 3) only a few cells in the restored adi-
pose tissue-rich stroma showed the presence of these two
matrix proteins, closely resembling the staining pattern
of the naive stroma (Figure 6A).
Staining for fibrogenic collagens III and V was slightly
enhanced in the hyperplastic lining cells; however, the
102-fold acute activation of expression of Col1a1 (Table 3)
was not seen as enhanced staining for collagen type I in
synovium (Figure 6B, Acute) or menisci (data not shown),
suggesting that Col1a1 transcripts are inefficiently trans-
lated or that the newly synthesized protein may not be
efficiently cross-linked and incorporated into synovium,
but instead diffuse into the synovial fluid.
As expected, the fibrotic tissue deposits seen in the peri-
meniscal synovium of the TTR group were robustly
stained for collagen type III, and to a lesser extent collagen
type I, which was mostly concentrated at the meniscus/
synovium interface, just like aggrecan and collagen type II
(Figure 6A). The vascular elements present in TTR sam-
ples (Figures 4A and 6) also stained positive for collagen
type III and V but in the TTR+HA group, all three fibro-
genic proteins were found only in the synovial cells.
Further, the alterations in staining for collagen type III
and V in these samples were consistent with the observed
decrease in fibrogenic gene expression (Table 3).
Effect of HA injection on the expression and abundance
of ADAMTS5 and MMP13 in cartilage/subchondral bone
and meniscus/synovium
The metalloproteinases ADAMTS5 and MMP13 are
investigated widely due to their apparent central role in
murine OA [16,30], and perhaps in human OA [18,31].
Expression of both Adamts5 (Table 4) and Mmp13
(Table 5) was detectable in both tissue pools for naïve
mice, and the expression of both was increased markedly
in cartilage/subchondral bone (approximately 6-fold) and
meniscus/synovium (approximately 50-fold) in the TTR
group, consistent with tissue remodeling. Notably, HA
injection (TTR+HA), essentially maintained the low
expression levels of both mmp13 and Adamts5 at the low
levels seen in the naïve tissues, whereas saline injection
(TTR+SA) was clearly ineffective in this regard.
Immunolocalization of ADAMTS5 in naïve joints
showed that it was abundant in a chondrocyte-associated
form (but not in matrix) throughout the articular carti-
lage and also in the synovial lining layer cells and matrix
(Figure 7, Naive). This is in keeping with our studies on
Table 2 QPCR of fibrogenic gene expression in cartilage/subchondral bone
col1a P Fold4 col3a P Fold4 col5a P Fold4
ΔCT1 ΔCT1 ΔCT1
Naive -0.84 (0.23) 1.00 6.67 (0.17) 1.00 9.98 (0.36) 1.00
Acute -6.03 (0.29) < .00012 36.5 5.10 (0.71) .0032 2.97 8.50 (0.41) .0122 2.80
TTR -6.02 (1.03) < .00012 36.2 2.95 (0.44) .00012 13.2 5.82 (1.02) .0012 17.9
TTR+HA -2.44 (0.52) .00023 3.03 5.08 (0.59) .00123 3.03 7.20 (0.44) .0293 6.87
TTR+SA -7.25 (1.84) NS3 84.4 3.15(1.09) NS3 11.5 4.87 (0.65) NS3 34.5
1relative to GAPDH, mean (SD) ΔCT of 8 pools with 2 mice per pool for Naïve and 12 pools with 2 mice per pool for all 4 treatment groups.
P-values: 2Acute or TTR vs Naive; 3TTR+HA or TTR+SA vs TTR;
4Fold Changes are relative to Naive
NS, not significant
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human cartilages where the enzyme was confined to the
pericellular matrix, and in association with HA [27]. For
the TTR group, MMP13 stained strongly in chondrocytes
and the surrounding matrix at the surface of the cartilage
lesions, and also in the underlying subchondral bone
cells. In addition, fibrotic tissue in the synovium of these
joints stained positive for MMP13 (Figure 7, TTR) and
this was particularly noticeable at the interface with the
Figure 5 Immunohistochemical analyses of chondrogenic and fibrogenic matrix molecules in cartilages of naïve and treated mice.
Typical examples of immunostained sections for each antibody, and a non-immune isotype control are shown for the four experimental groups
(Naïve, Acute, TTR and TTR+HA). Details of antibodies and staining conditions used are described in the Methods Section. (A) Enhanced staining
for chondrogenic proteins (A) and fibrogenic proteins (B) in Acute and TTR+HA conditions are highlighted by black stars, and staining in lesional
area of the TTR condition are marked by black arrowheads.
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meniscal tissue (black arrow). As predicted from the gene
expression studies (Table 5), HA injection prior to tread-
mill running (TTR+HA) essentially prevented the
increase in MMP13 protein abundance seen in the
cartilage and synovium of the TTR group. IHC for
ADAMTS5 showed that in the TTR group there was a
markedly enhanced pericellular staining associated with
both flattened cells lining cartilage lesions and underlying
cell groups (Figure 7, TTR, black arrow heads). In addi-
tion, both cells and matrix were stained throughout the
fibrotic regions of the synovium. HA injection before
treadmill running (TTR+HA) essentially prevented the
increased staining for ADAMTS5 of chondrocytes, and
their associated matrix at the cartilage surface. It was
notable that for TTR+HA samples, the synovial lining
cells and stromal cells in the adipose tissue maintained
strong staining for ADAMTS5, whereas mRNA levels in
the relevant meniscus/synovium samples were reduced
(Table 3).
Lastly, while no statistical evaluation of the meniscus/
synovium data (Tables 2, 3 and 5) was possible, the con-
clusions were based on the following considerations.
First, the differences in gene expression between the TTR
(or TTR +saline) group and the TTR+HA group was
always very marked, being about 4-fold (Acan),16-fold
(Col2a1),10-fold (Col10a1),15-fold (Col1a1),4-fold
(Col3a1),10-fold (Col5a1),10- to 40-fold (Adamts5) and
10- to 30-fold (Mmp13). This makes it highly likely that
the differences found in tissues pooled from 8 to 12 mice
are biologically relevant to the effects of HA. In addition,
as described repeatedly in the text above, the changes in
expression for each gene evaluated were often supported
by changes seen in abundance of the equivalent proteins
by IHC.
Effect of HA injection on the macroscopic pathology seen
in CD44 knockout mice
While studies with neutralizing CD44 antibodies have
implicated CD44 in the inhibitory effects of HA on
expression of metalloproteinases by chondrocytes and
synoviocytes [19-22], it has also been shown with isolated
fibroblasts that their transition to myofibroblasts, a
feature of fibrotic remodeling, is modulated by the inter-
action of CD44 with HA [32]. Since enhanced expression
of metalloproteinases and fibrotic remodeling was also
seen in joint tissues after TTR, and this was reversed by
HA in vivo, we decided to further examine the need for
CD44 in the protective effects of HA injection. For this
purpose we subjected Cd44-/- mice [17] to the TTR
model and examined the extent to which HA injection
was joint protective in the absence of CD44. The macro-
scopic pathologies seen (Figure 8) clearly indicated that
CD44 was essential for the HA effects, suggesting that
the binding of the injected HA to cell surface CD44 is
essential for its cartilage protection and anti-fibrotic
activities in this murine OA model.
Discussion
The mechanism by which injected HA exerts CD44-
dependent anti-fibrotic effects in murine OA appears
related to the finding [33] that the fibroblast to myofibro-
blast transition in progressive murine lung fibrosis is also
modulated by HA in a CD44-dependent fashion. In a simi-
lar way, it has been shown [34] that HA exhibits a CD44-
dependent protection against LPS-induced murine sepsis
by binding to TLR4 and blocking excessive inflammatory
cytokine production. In this context, we set out to deter-
mine whether the cartilage-protective effects of intra-
articular HA operate thru a CD44-dependent modulation
of the chondrogenic/fibrogenic gene response pathways
and/or thru changes in the expression of the critical metal-
loproteinases, ADAMTS5 and MMP13. Based on the find-
ing that cartilage degradation in the TTR model follows
the formation of fibrotic tissue deposits, we hypothesized
that it would be associated with the high expression of
fibrogenic genes, relative to chondrogenic, and that HA-
mediated protection would operate through a reversal to
high chondrogenic expression.
To summarize the results (Table 6), we found that in the
acute phase of the model (Days 0 to 5), and before evi-
dence of any cartilage lesions, there was a generalized
increase in expression of both chondrogenic and fibro-
genic genes in both tissue compartments (presumably a
direct anabolic response to TGFbeta1 injection). After
Table 3 QPCR of chondrogenic and fibrogenic gene expression in meniscus/synovium
acan Fold2 col2a Fold2 col10a Fold2 col1a Fold2 col3a Fold2 col5a Fold2
ΔCT1 ΔCT1 ΔCT1 ΔCT1 ΔCT1 ΔCT1
Naive 3.28 1.00 3.73 1.00 5.50 1.00 -0.21 1.00 0.05 1.00 3.46 1.00
Acute -0.89 17.5 -1.59 39.9 1.92 11.9 -6.89 102 -0.13 1.13 1.43 4.08
TTR 0.79 5.61 -1.41 35.3 1.35 17.7 -4.90 25.8 -3.66 13.1 -1.40 29.0
TTR+HA 2.99 1.22 2.63 2.10 4.76 1.67 -1.45 2.43 -1.11 2.23 2.12 2.53
TTR+SA 1.10 4.53 -1.25 31.5 1.46 16.4 -6.10 59.3 -2.68 6.63 -0.98 21.7
1relative to GAPDH, mean (SD) ΔCT of 2 pools with 8 mice per pool for Naïve and 2 pools with 12 mice per pool for all 4 treatment groups. Values represent the
average of the two pools, with the difference between duplicates being < 20% of average pool value.
2Fold Changes are relative to Naive
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TTR, and in the presence of tissue fibrosis and cartilage
erosion, the chondrogenic genes in both tissue compart-
ments had essentially normalized to naïve levels, except
for Col2a1 and Col10a1, which remained elevated in the
meniscus/synovium. At the same time, the fibrogenic
genes in both tissue compartments remained elevated or
Figure 6 Immunohistochemical analyses of matrix components in the lateral perimeniscal synovium of naïve and treated mice. Typical
examples of immunostained sections for each antibody, and a non-immune isotype control are shown for the four experimental groups (Naïve,
Acute, TTR and TTR+HA). Enhanced staining of aggrecan and collagen II in the hyperplastic (Acute and TTR+HA) and fibrotic regions (TTR) are
indicated by black arrow heads. For the TTR condition, strong staining with anti-collagen II or V was seen in the fibrotic regions, as well as
around groups of meniscal fibrochondrocytes, and vascular elements stained positively with anti-collagen V. In all treatment groups, collagen X
staining patterns were essentially identical to those seen for collagen II (data not shown). L, Lining; S, Stroma.
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even increased further, particularly in the cases of Col3a1
and Col5a1. In addition, the expression levels of both
Adamts5 and Mmp13 were markedly increased in both
tissue compartments in the TTR model. These results are
consistent with the idea that cartilage degradation is due
to a high expression of fibrogenic genes relative to chon-
drogenic genes, and also due to a high expression of the
metalloproteinases known to be involved in the degrada-
tive cascade.
Most importantly, in terms of understanding the
mechanism of HA-mediated protection, it was found that
HA injection resulted in activation (relative to saline injec-
tion) of chondrogenic genes in the cartilage/subchondral
bone and a diminution of fibrogenic genes in both tissue
compartments. Further, HA injection resulted in a nor-
malization of expression of Adamts5 and Mmp13 in both
compartments. These results indicate that HA-mediated
protection is due to a repression of fibrogenesis and an
enhancement of chondrogenesis in the cartilage/subchon-
dral bone along with a lowering of the expression of the
relevant metalloproteinases in both compartments.
At the histological level, (Figure 6), when TTR samples
are examined together with the naïve and acute sections, it
is apparent that TGFbeta1 treatment alone results in the
appearance of cells with a fibrogenic pericellular/cell-asso-
ciated matrix, and that during the biomechanical challenge
of treadmill running, this cell population is markedly
diminished as the surface layer is eroded. However, when
HA is injected before treadmill usage (TTR+HA), the
fibrogenic pool of cells and associated matrix remains
intact. Taken together, the data suggest that HA prevents
the catabolic response of chondrocytes which are sur-
rounded by a fibrogenic ECM. In this context, treadmill
running alone for 14 days results in only minimal cartilage
thinning on the femoral condyles [26] and, although tread-
mill alone stimulates Col1a1 (approximately four-fold) and
Col2a1 (approximately seven-fold) expression (but not
other collagens), this did not cause a detectable accumula-
tion of fibrogenic collagens in the pericellular/cell-asso-
ciated space (data not shown). It is likely that cartilage
erosion in this model is ultimately driven by “catabolic”
soluble mediators and one possible source is the mixture
of cell types of the remodeled synovial lining. In this con-
text Hematoxylin/Eosin histology of the perimeniscal
synovium (Figure 4) showed that HA prevented both
fibrotic remodeling and neovascularization, in keeping
with the observed inhibition of profibrotic gene expression
(Table 3). An associated effect of HA during treadmill run-
ning is inhibition of TGFbeta1-induced chondrogenic gene
induction in the synovium/meniscus (Table 3), which sug-
gests that the elimination of both fibrotic and chondro-
genic cells might promote restoration of the homeostatic
adipose-rich stroma of the synovium.
It should be noted that with respect to changes in gene
expression, the results were obtained with samples con-
taining more than one type of tissue. In one case it was
tibial and femoral cartilage with attached subchondral
bone, and in the other it was the lateral and medial
menisci with attached synovium. It is, therefore, not possi-
ble to discern which cell-types were most affected at the
gene expression level by the injection of hyaluronan. How-
ever, the immunohistochemical studies did illustrate that
in most cases all tissues exhibited protein changes consis-
tent with the alterations in gene expression observed.
A more mechanistic insight into the effects of HA injec-
tion seen in this study is suggested by our studies with
Cd44-/- mice (Figure 8). We have previously reported that
CD44, together with pericellular aggrecan and HA can act
as a potent inhibitor of profibrogenic TGFbeta1 signaling
in dermal wound healing [17]. This could at least in part
be explained by a shift from an ALK5/SMAD2,3 (fibro-
genic) to an ALK1/SMAD1,5,8 (chondrogenic) signaling
response. The requirement for CD44 in HA-mediated pro-
tection from joint degradation in this OA model indicates
that the injected HA interacts with cell surface CD44 and,
Table 4 QPCR of Adamts5 expression in cartilage/
subchondral bone and meniscus/synovium
CARTILAGE/SC BON MENISCUS/SYNOVIUM
Adamts5 P Fold 5 Adamts5 Fold5
ΔCT1 ΔCT1
Naive 8.85 (0.55) 1.00 8.31 1.00
TTR 5.94 (0.44) .00173 7.51 1.90 85.1
TTR+HA 7.56 (0.86) .0414 2.44 5.35 7.84
TTR+SA 6.22 (1.24) .0094 6.20 -0.17 357
1relative to GAPDH, mean (SD) ΔCT of 8 pools with 2 mice per pool for Naïve
and 12 pools with 2 mice per pool for all 4 treatment groups.
2relative to GAPDH, mean (SD) ΔCT of 2 pools with 8 mice per pool for Naïve
and 2 pools with 12 mice per pool for all 4 treatment groups. Values
represent the average of the two pools, with the difference between
duplicates being < 20% of average pool value. P-values: 3TTR vs Naive; 4TTR
+HA or TTR+SA vs TTR;
5Fold Changes are relative to Naive
Table 5 QPCR of mmp13 expression in cartilage/
subchondral bone and meniscus/synovium
CARTILAGE/SC BONE MENISCUS/SYNOVIUM
mmp13 P Fold 5 mmp13 Fold5
ΔCT1 ΔCT1
Naive 4.74 (0.9) 1.00 14.10 1.00
TTR 1.95 (1.01) .0043 5.73 9.56 23.3
TTR+HA 3.50 (1.11) .0454 1.95 13.15 1.93
TTR+SA 1.12 (0.75) .0034 12.30 7.89 74.4
1relative to gapdh, mean (SD) (Delta symbol) CT of 8 pools with 2 mice per
pool for Naïve and 12 pools with 2 mice per pool for all 4 treatment groups.
2relative to gapdh, mean (SD) (Delta symbol) CT of 2 pools with 8 mice per
pool for Naïve and 2 pools with 12 mice per pool for all 4 treatment groups.
Values represent the average of the two pools, with the difference between
duplicates being <20% of average pool value. p values: 3TTR vs Naive; 4TTR
+HA or TTR+SA vs TTR; 5Fold Changes are relative to Naive.
Li et al. Arthritis Research & Therapy 2012, 14:R151
http://arthritis-research.com/content/14/3/R151
Page 12 of 16
thereby, mediates a switch from fibrogenesis to chondro-
genesis in the cartilage and adipogenesis in the activated
stromal cell population (Figure 4). This hypothesis is
strengthened by the knowledge that chondrogenesis and
adipogenesis are known to be promoted by strong BMP/
ALK1/Smad1/5/8 signaling [35].
A proposed molecular mechanism for joint protection by
HA
The current study shows that HA injection, when used
soon after a joint insult, can inhibit the cascade of OA-like
changes which occur in the cartilage/subchondral bone
and meniscus/synovium (the data are summarized in
Table 6). This protective effect of HA has also been
demonstrated convincingly in a range of other animal
models of OA [3-7,36]. However, uncovering the central
process by which HA operates will clearly require further
work to delineate its effects on the fate of proliferated
synovial stromal cells and also on soluble mediator pro-
duction during biomechanical stimulation. For example,
HA may prevent the CD44-dependent transition of
TGFbeta1-activated stromal cells to a stable myofibroblas-
tic phenotype, much as demonstrated in human fibroblast
differentiation [37,38]. Indeed, such a process might pre-
vent the appearance of contractile myofibroblasts in
human OA cartilage [39]. In addition, HA may reduce
apoptosis [40], which in turn could reduce fibrotic remo-
deling by modulating innate immune responses, as shown
for alveolar epithelial cells in lung fibrosis [41].
Conclusions
We speculate that any beneficial effects of HA injection
on pain and function in OA patients [1] result from a
normalization of the synovial content of pro-inflamma-
tory and pro-catabolic mediators, which appear to be
responsible for cartilage erosion in human OA [42-45].
Such a pathway is consistent with the finding that patient
benefit from HA injection appears to depend on the
stage and/or sub-type of OA being treated [1,46,47].
Since the therapeutic effects of HA injection described
here, and elsewhere, appear to depend largely on its anti-
fibrotic activity it is possible that the combined use of
HA and an anti-fibrotic agent might improve efficacy. In
this regard, it is probably relevant that dosing of rats with
GW788388, an agent which has anti-fibrotic effects
through inhibition of ALK5, also results in excessive car-
tilage matrix deposition in the growth zone [48]. Indeed,
this is consistent with our suggestion [49] that inhibition
of ALK5 in joint progenitor cells will result in a switch
from degenerative fibrosis to reparative chondrogenesis
Figure 7 Immunohistochemical analyses of ADAMTS5 and MMP13 in cartilages and perimeniscal synovium of naïve and treated mice.
(A) Immunohistochemical staining patterns form ADAMTS5 and MMP13. Chondrocytes throughout the depth of cartilage showed intense cell-
associated staining for ADAMTS5 in all treatment groups. Cells and matrix in hyperplastic (TTR and TTR+HA), or fibrotic (TTR) regions of the
synovium and cartilage lesions (TTR) also showed abundant immunoreactive ADAMTS5. (B) MMP13 staining was seen only in the pericellular
space of chondrocytes in TTR samples, and the matrix at the meniscal/synovial interphase (marked by black arrows).
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in the articular cartilage. Finally, the lack of protection of
HA against macroscopic OA pathology in the Cd44-/-
mouse, provides the opportunity to examine in future
experimentation, which cell types are primarily involved
in the HA-CD44 mediated therapeutic responses in the
knee joint in this murine OA model.
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Metalloproteinase with Thrombospondin Motifs 5; EDTH:
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Figure 8 Menisci and cartilage surfaces of Cd44-/- mice show lack of protection by intra-articular HA injections. Cd44-/- male mice were
subjected to the TTR model without (n = 4) or with (n = 4) intra-articular HA injections. Knee joints from those treated mice as well as naïve (n
= 4) treated mice were examined by India Ink application, photography under a Nikon dissecting microscope (SMZ1000, X6) and images
processed with Spot Basic, Diagnostic Instruments, Inc. Typical images of meniscus and cartilage surfaces from naïve joints (top row) and joints
from the TTR group (second row) and TTR+HA group (third rows) are shown. Black arrow heads indicate cartilage erosion and black stars
indicate fibrotic overgrowth. See Figure 2 for equivalent images from wild-type mice.
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